Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Impact BioMedicalIBO -1.57%10 PB Ratio is 4.40 as of Aug. 14, 2026, which is 4% below its 10-year median of 4.56. GuruFocus rates IBO with a GF Score™ of 10/100. The stock has 6 warning signs investors should review. Among 1,220 Biotechnology companies, Impact BioMedical ranks worse than 65.66% on this metric.
The historical rank and industry rank for Impact BioMedical's PB Ratio or its related term are showing as below:
IBO'
s PB Ratio Range Over the Past 10 Years
Min: 3.6 Med: 4.56 Max: 6.49
Current: 4.4
During the past 7 years, Impact BioMedical's highest PB Ratio was 6.49. The lowest was 3.60. And the median was 4.56.
IBO's PB Ratio is ranked worse than 65.66% of 1220
companies
in the Biotechnology industry
Industry Median: 2.9
vs IBO: 4.40
During the past 3 years, the average Book Value Per Share Growth Rate was -63.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -48.40% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Impact BioMedical was 616.10% per year. The lowest was -63.90% per year. And the median was -32.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Impact BioMedical PB Ratio Related Terms
Impact BioMedical PB Ratio Historical Data
* Premium members only.
The historical data trend for Impact BioMedical's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Impact BioMedical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impact BioMedical PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Impact BioMedical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Impact BioMedical's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Impact BioMedical (IBO) has a PB Ratio of 4.40 as of Aug. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Impact BioMedical and its competitors. This is near median its historical median of 4.56. Over the past decade, Impact BioMedical's PB Ratio has ranged from 3.60 to 6.49. According to the industry distribution chart, Impact BioMedical ranks #801 out of 1220 companies in the Biotechnology industry, placing it in the top 65.7%.
Is Impact BioMedical's PB Ratio too high?
Impact BioMedical's current PB Ratio of 4.40 is near median its 10-year median of 4.56. Over the past 10 years, this metric has ranged from a low of 3.60 to a high of 6.49. The Biotechnology industry median PB Ratio is 2.90. Impact BioMedical's value of 4.40 is 51.7% above this industry median. Based on the distribution chart, Impact BioMedical ranks #801 out of 1220 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Impact BioMedical has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Impact BioMedical's PB Ratio compare to ATYR and MCRB?
According to the Biotechnology industry distribution chart, Impact BioMedical ranks #801 out of 1220 companies for PB Ratio. This places Impact BioMedical in the lower half of its industry. The industry median PB Ratio is 2.90. Impact BioMedical's value of 4.40 is 51.7% above this benchmark. Historically, Impact BioMedical's own PB Ratio has ranged from 3.60 to 6.49 over the past decade. While the company's 10-year median is 4.56 vs. the industry median of 2.90, Impact BioMedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,220 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Impact BioMedical's current PB Ratio of 4.40 is 51.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Impact BioMedical and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impact BioMedical's current PB Ratio is 4.40, which is near median its own 10-year median of 4.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impact BioMedical stock overvalued right now?
Impact BioMedical (IBO) has a current PB Ratio of 4.40. The current PB Ratio is 4.40, which is near median its 10-year median of 4.56 and 51.7% above the Biotechnology industry median of 2.90. Impact BioMedical's overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Impact BioMedical (IBO), the current PB Ratio is 4.40 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
10GF Score
Get the complete analysis for IBO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBO has been successfully added to your 
